Sourcing & GuidesAesthetic DevicesSkincare OEM

【South Korea】Enchem Life Sciences Targets $7.68B Global PDRN/PN Market with Full Vertical Integration

Jun 17, 2026Local score 9.8

Source image preserved for article context.

Editor's note

This piece draws on Ministry of Oceans and Fisheries data to signal a $7.68B market opportunity, but buyers should weigh regulatory convergence risks in China and Vietnam, where product classification as cosmetics or medical devices remains fluid, potentially affecting supply-chain compliance.

South Korea's Enchem Life Sciences is pursuing full vertical integration for PDRN (polydeoxyribonucleotide) and PN (polynucleotide) regenerative biomaterials, aiming to capture a share of the global market valued at $7.68 billion (approx. KRW 10.61 trillion) in 2025. The strategy covers raw material production, efficacy validation, and finished product commercialization, positioning the company to serve growing medical aesthetics demand in Asia.

Market signal

According to the Ministry of Oceans and Fisheries, the global PDRN/PN market reached $7.68 billion in 2025, driven by surging demand in medical aesthetics beyond traditional wound healing and orthopedics. Applications in skin regeneration, wrinkle improvement, and hair management are expanding rapidly, making these biomaterials key for aesthetic clinics and product developers.

Technology and production edge

Enchem Life Sciences has internalized high-efficiency nucleic acid extraction technology from salmon testes and developed a 'molecular weight control process' that enables production of both low- and high-molecular-weight PDRN tailored to specific applications. This process optimizes viscosity and skin applicability, enhancing formulation flexibility. The company has filed patents for the process and skin health improvement uses.

Quality and efficacy validation

The company targets high-purity raw materials with a 260/280 ratio of 1.8–2.0 and is introducing ultrafiltration-based purification to manage protein impurities, microorganisms, endotoxins, and molecular weight distribution. Cell-based tests have shown significant data on soothing problematic skin and strengthening skin barriers, with ongoing comparative studies against commercial competitors to confirm at least equivalent efficacy.

Commercialization and channel strategy

Enchem Life Sciences is pursuing a three-track strategy: raw material supply, finished product production, and overseas expansion. It is currently producing skin booster samples and expanding its finished product lineup. A recent joint research agreement for 'functional pharmacopuncture materials based on PDRN and natural products' extends its reach into Korean medicine and medical institution channels.

What buyers should watch

The company's primary overseas targets are China and Vietnam, leveraging local regulatory environments that favor convergence products combining cosmetics and medical devices. Enchem plans to collect trouble-care data and consumer efficacy evaluations in major Asian beauty markets to refine region-specific raw material positioning. Importers and distributors should monitor its patent portfolio and quality standardization progress for potential supply partnerships.

Source: Read the original report | Published: June 17, 2026